A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Background: The efficacy of naltrexone, baclofen, and acamprosate in the treatment of alcohol dependence has been successfully established over the past several years. The knowledge about their relative efficacies can facilitate in developing relapse prevention strategies that would give rise to a greater personal and socioeconomic benefits. Aims and Objective: To assess and compare the safety and efficacy profile of naltrexone, baclofen, and acamprosate in the treatment of alcohol dependence. In addition to this, the pattern of relapse and attitude of patients toward the treatment were also assessed. Materials and Methods: This was a prospective study carried out at a tertiary care center. It comprised of thirty alcohol-dependent patients each assigned to naltrexone, baclofen, and acamprosate group after detoxification. The patients were assessed for craving, relapse risk, and medication adherence using the respective scales and questionnaires. Results: In terms of Obsessive Compulsive Drinking Scale score decline, the decline seen in the naltrexone group (26.72 ± 13.05) was maximum, followed by baclofen and acamprosate. In terms of decreasing Advance Warning of Relapse (AWARE) questionnaire score, again naltrexone was most effective, with the maximum decline in AWARE score (64.72 ± 45.65), followed by baclofen and acamprosate. The attitude toward treatment with all the three medications was positive, as per the Hogan Drug Attitude Inventory score. Conclusion: Naltrexone was most effective in decreasing craving and drinking behavior. Baclofen showed best tolerability in terms of liver function tests and least number of side effects reported. Naltrexone group reported the least number of relapses but maximum number of side effects. Acamprosate group had the maximum dropout rate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two studies with 171 participants comparing active pharmacologic interventions reported on alcohol consumption. These studies found evidence of a reduced likelihood of remission among participants who were allocated to receive acamprosate as compared to another active pharmacologic treatment (baclofen, disulfiram, or naltrexone; RR = 0.58, 95% CI 0.42 to 0.79; n = 2 trials, 171 participants; Heter”
From Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries (2023) · cites this paper as Kumar 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487
Hogan, T. P., Awad, A. G., & Eastwood, R. (1983) · Psychological Medicine · doi:10.1017/s0033291700050182 · Cited by 1,028
Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., Abenavoli, L., D'Angelo, C., Caputo, F., Zambon, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61814-5 · Cited by 685
Anton, R. F. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830030047008 · Cited by 511
Maisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04054.x · Cited by 470
Mayo-Smith, M. F. (1997) · JAMA · doi:10.1001/jama.278.2.144 · Cited by 434
Naltrexone and Alcohol Dependence: Role of Subject Compliance
Volpicelli, J. R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200071010 · Cited by 411
Chick, J. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.6.587 · Cited by 310
Garbutt, J. C., Kampov‐Polevoy, A. B., Gallop, R., Kalka‐Juhl, L., & Flannery, B. A. (2010) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01273.x · Cited by 294
Myrick, H., Anton, R. F., Li, X., Henderson, S., Randall, P. K., & Voronin, K. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.4.466 · Cited by 258 · cited 1×
“[4] Acamprosate has been a proven safe and well-tolerated treatment modality for alcohol dependence since its introduction in Europe in 1989.”
Research works printed but not linked: 1
- Mishra, 2010, A study of comparative efficacy of Baclofen vs. acamprosate in reducing alcohol craving and abuse, Indian Journal of Psychiatry, 52, S69
Cited by
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease
Ayyala, D., Bottyan, T., Tien, C., Pimienta, M., Yoo, J., Stager, K., Gonzalez, J. L., Stolz, A., Dodge, J. L., Terrault, N. A., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2080 · Cited by 59
Baclofen for alcohol use disorder
Agabio, R., Saulle, R., Rösner, S., & Minozzi, S. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557.pub3 · Cited by 75
Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder
Lohoff, F. W. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.767506 · Cited by 43
Stokłosa, I., Więckiewicz, G., Stokłosa, M., Piegza, M. J., Pudło, R., & Gorczyca, P. W. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20031870 · Cited by 37
Martins, B. S., Rutland, W., Aquino, J. P. D., Kazer, B., Funaro, M. C., Potenza, M. N., & Angarita, G. A. (2022) · Current Addiction Reports · doi:10.1007/s40429-022-00432-9 · Cited by 12
Metadata
- Authors
- Kumar, A., Sharma, A., Bansal, P. D., Bahetra, M., Gill, H. K., & Kumar, R.
- Affiliations
- Guru Gobind Singh Medical College and Hospital (IN)
- Corresponding author
- Sharma, Arvind
- ORCID
- Kumar, Rakesh
- Venue
- Indian Journal of Psychiatry
- Published
- 2020-11
- Volume
- 62
- Issue
- 6
- Pages
- 650-658
- ISSN
- 0019-5545 (ISSN-L)
- PMC
- PMC8052868
- OpenAlex
- W3110924486
- Semantic Scholar
- 69f5e452845111b77f1280d9d6cd774687a708de
- Cited by
- 21
- References
- 22
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 4 · 2022: 5
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Indian Journal of Psychiatry (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Keywords
- alcoholism, naltrexone, baclofen, acamprosate, relapse prevention, craving, medication adherence, adverse drug reactions, treatment discontinuation, treatment attitudes, alcohol detoxification, liver function tests
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. https://app.cochat.ai/papers/10.4103/psychiatry.indianjpsychiatry_201_19
- The paper
- Kumar, A., Sharma, A., Bansal, P. D., Bahetra, M., Gill, H. K., & Kumar, R. (2020). A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_201_19
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.